4xe2: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==N-terminal domain of Hsp90 from Dictyostelium discoideum in complex with peptide== | ==N-terminal domain of Hsp90 from Dictyostelium discoideum in complex with peptide== | ||
<StructureSection load='4xe2' size='340' side='right' caption='[[4xe2]], [[Resolution|resolution]] 1.20Å' scene=''> | <StructureSection load='4xe2' size='340' side='right' caption='[[4xe2]], [[Resolution|resolution]] 1.20Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[4xe2]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4XE2 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4XE2 FirstGlance]. <br> | <table><tr><td colspan='2'>[[4xe2]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Atcc_11735 Atcc 11735]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4XE2 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4XE2 FirstGlance]. <br> | ||
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4xe2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4xe2 OCA], [http://pdbe.org/4xe2 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4xe2 RCSB], [http://www.ebi.ac.uk/pdbsum/4xe2 PDBsum]</span></td></tr> | </td></tr><tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">hspD, hsc90, hsp90, DDB_G0267400 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=44689 ATCC 11735])</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4xe2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4xe2 OCA], [http://pdbe.org/4xe2 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4xe2 RCSB], [http://www.ebi.ac.uk/pdbsum/4xe2 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4xe2 ProSAT]</span></td></tr> | |||
</table> | </table> | ||
== Function == | == Function == | ||
| Line 20: | Line 22: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Atcc 11735]] | |||
[[Category: Raman, S]] | [[Category: Raman, S]] | ||
[[Category: Suguna, K]] | [[Category: Suguna, K]] | ||
Revision as of 12:33, 22 November 2017
N-terminal domain of Hsp90 from Dictyostelium discoideum in complex with peptideN-terminal domain of Hsp90 from Dictyostelium discoideum in complex with peptide
Structural highlights
Function[HSC90_DICDI] Molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved for instance in cell cycle control and signal transduction. Undergoes a functional cycle that is linked to its ATPase activity. This cycle probably induces conformational changes in the client proteins, thereby causing their activation. Interacts dynamically with various co-chaperones that modulate its substrate recognition, ATPase cycle and chaperone function (By similarity). Publication Abstract from PubMedThe involvement of Hsp90 in progression of diseases like cancer, neurological disorders and several pathogen related conditions is well established. Hsp90, therefore, has emerged as an attractive drug target for many of these diseases. Several small molecule inhibitors of Hsp90, such as geldanamycin derivatives, that display antitumor activity, have been developed and are under clinical trials. However, none of these tested inhibitors or drugs are peptide-based compounds. Here we report the first crystal structure of a peptide bound at the ATP binding site of the N-terminal domain of Hsp90. The peptide makes several specific interactions with the binding site residues, which are comparable to those made by the nucleotide and geldanamycin. A modified peptide was designed based on these interactions. Inhibition of ATPase activity of Hsp90 was observed in the presence of the modified peptide. This study provides an alternative approach and a lead peptide molecule for the rational design of effective inhibitors of Hsp90 function. First Structural View of a Peptide Interacting with the Nucleotide Binding Domain of Heat Shock Protein 90.,Raman S, Singh M, Tatu U, Suguna K Sci Rep. 2015 Nov 24;5:17015. doi: 10.1038/srep17015. PMID:26599366[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||